A research group from IDIBELL and ICO have presented an oncolytic virus that stimulates the anti-tumor response of NK cells and helps slow the growth of cancer.
Scientists present an oncolytic virus targeting NK cells with great antitumor potential Read More »
A study published in Circulation offers unprecedented perspectives on the molecular mechanisms that lead to Hereditary Hemorrhagic Telangiectasia
Scientists find a new mechanism that explains the development of vascular malformations Read More »
It is one of the winning initiatives of the 2023 call for grants, which is the result of a collaboration agreement between the charity institution and the council.
The grant, of €2,500,000, will promote the Smart Health Community project
IDIBELL receives FORTALECE grant from the Carlos III Health Institute Read More »
The use of this massive genetic sequencing platform could improve patient survival thanks to the detection of therapeutic targets and mutations that predispose to cancer.
A study led by Dr. Sara Larriba’s team at IDIBELL, in collaboration with Fundació Puigvert and IGTP, demonstrates that the concentration of microRNAs and their isoforms in semen samples may reflect alterations in sperm production.
Researchers from IDIBELL and ICO have used computational models to analyze bone marrow transplant data from 33,927 patients and develop a tool that provides personalized estimates of mortality from this type of therapies.
Artificial intelligence helps take decisions about bone marrow transplant Read More »
A team of international researchers has identified the specific processes by which the MYC oncogene promotes this disease and, this way, demonstrated that this gene can attack specific weaknesses in tumor cells.
Scientists open up a new way to fight cancer through the MYC gene Read More »
The research group has managed to demonstrate the good results of an algorithm that adjusts the doses of the immunosuppressant tacrolimus according to the characteristics of each person. The results have been published in the scientific journal Kidney International.
The model has been created by injecting tumor cells from a patient into a mouse to mimic the transformation of leukemia into a more aggressive form, making it possible to learn about the real evolution of the disease and be able to test new treatments.
